Review of the clinical evidence for interferon β 1a (Rebif®) in the treatment of multiple sclerosis
Francesco Manfredonia1, Livia Pasquali1, Angela Dardano2, Alfonso Iudice1, Luigi Murri1, Fabio Monzani21Department of Neuroscience and 2Department of Internal Medicine, University of Pisa, Pisa, ItalyAbstract: Interferon (INF) β 1a 22 or 44 µg (Rebif®) administ...
Guardado en:
Autores principales: | Francesco Manfredonia, Livia Pasquali, Angela Dardano, Alfonso Iudice, Luigi Murri, Fabio Monzani |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f9ba7fc011e5483988eb9c66774311ef |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Early stage and long term treatment of multiple sclerosis with interferon-β
por: Angela Applebee, et al.
Publicado: (2009) -
An update on the toxicity of Aβ in Alzheimer’s disease
por: Jürgen Götz, et al.
Publicado: (2008) -
Brain amyloid β protein and memory disruption in Alzheimer’s disease
por: Weiming Xia
Publicado: (2010) -
Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
por: Castrop F, et al.
Publicado: (2013) -
An update on the use of Atripla® in the treatment of HIV in the United States
por: Michael A Horberg, et al.
Publicado: (2010)